Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Recombinant tissue plasminogen activator (rt-PA) is currently the most commonly used
thrombolytic drug in patients with pulmonary thromboembolism (PTE). Optimal dosing with
maximal benefits and minimal risks is of great importance. Considering the lower body weight
in general Chinese population, we compared the efficacy and safety of lower dose rt-PA
50mg/2h regimen with the FDA-approved rt-PA 100mg/2h regimen in selected PTE patients.